Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut and focused on targeted protein degradation. Its news flow centers on progress across a pipeline of investigational PROTAC (PROteolysis TArgeting Chimera) protein degraders for oncology and neurodegenerative disorders.
On this ARVN news page, readers can follow company-issued updates on key programs such as vepdegestrant, an investigational PROTAC estrogen receptor degrader for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations; ARV-393, a BCL6 degrader in Phase 1 trials for relapsed/refractory non-Hodgkin lymphoma; ARV-806, a KRAS G12D degrader for solid tumors including pancreatic, colorectal and lung cancer; and ARV-102, a LRRK2 degrader being studied in Parkinson’s disease and other neurodegenerative conditions.
Typical ARVN news items include clinical data presentations at major scientific meetings, regulatory milestones such as acceptance of the New Drug Application for vepdegestrant by the U.S. Food and Drug Administration, and preclinical results that characterize the activity of new PROTAC candidates. Arvinas also uses press releases to describe collaboration developments with Pfizer, organizational changes, financial updates and other corporate actions disclosed in its SEC filings.
Investors, clinicians and researchers can use this news feed to track how Arvinas’ PROTAC platform is being applied to targets like estrogen receptor, BCL6, KRAS G12D and LRRK2, and to monitor the timing and content of data readouts, regulatory events and partnership announcements related to ARVN.
Arvinas, Inc. (Nasdaq: ARVN) has announced updated safety and efficacy data for ARV-110, a PROTAC protein degrader, during the upcoming 2020 ASCO Annual Meeting. The Phase 1/2 trial targets men with metastatic castration-resistant prostate cancer, showing promising results, including ongoing PSA responses in two patients. The trial has successfully enrolled patients heavily pre-treated with standard therapies such as enzalutamide and abiraterone. Data highlights a sustained safety profile supporting further dose escalation, marking a significant milestone for Arvinas' innovative therapeutic approach.